Corcept Therapeutics Incorporated (CORT)

Debt-to-equity ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 679,589 638,835 596,243 547,864 506,705 461,679 421,614 529,584 501,842 473,364 442,326 407,811 375,806 540,229 522,675 510,802 523,338 489,680 453,698 409,489
Debt-to-equity ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $679,589K
= 0.00

Corcept Therapeutics Incorporated has consistently maintained a debt-to-equity ratio of 0.00 throughout the reporting periods from March 31, 2020, to December 31, 2024. This indicates that the company has not utilized any debt financing to fund its operations or investments, relying solely on equity financing. A debt-to-equity ratio of 0.00 signifies that the company's liabilities are virtually non-existent in relation to its equity, suggesting a strong financial position with minimal financial risk. The company's ability to operate without relying on debt indicates financial stability and potential lower default risk. Overall, the consistent 0.00 debt-to-equity ratio reflects a conservative financial strategy and a strong capital structure for Corcept Therapeutics Incorporated.